Payment overview · 2025
General Payments
$429.48
16 reported records · 9 companies
Healthcare provider profile · identity verified
Timbi D West, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CHARLESTON, AR · NPI 1508853466
Verified facts
What the public records show
CMS Open Payments records show Timbi D West, APRN received $429.48 in general payments during 2025 across 16 reported records.
AstraZeneca Pharmaceuticals LP accounted for 39.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $168.03 | 39.1% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $72.81 | 16.9% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $42.91 | 10.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.00 | 9.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.58 | 8.5% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $24.03 | 5.6% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.80 | 3.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.28 | 3.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.04 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $429.48 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $152.94 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $72.81 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $43.08 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $42.91 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $41.00 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $41.00 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.58 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $27.99 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 404 | 87 |
| Atorvastatin Calcium | Atorvastatin Calcium | 386 | 93 |
| Lisinopril | Lisinopril | 253 | 57 |
| Losartan Potassium | Losartan Potassium | 235 | 54 |
| Gabapentin | Gabapentin | 234 | 63 |
| Potassium Chloride | Potassium Chloride | 222 | 46 |
| Furosemide | Furosemide | 207 | 40 |
| Tramadol Hcl | Tramadol Hcl | 204 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 201 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 201 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 194 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 185 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 177 | 54 |
| Sertraline Hcl | Sertraline Hcl | 153 | 36 |
| Meloxicam | Meloxicam | 145 | 42 |
| Trazodone Hcl | Trazodone Hcl | 144 | 32 |
| Amlodipine Besylate | Amlodipine Besylate | 143 | 29 |
| Carvedilol | Carvedilol | 143 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 137 | 28 |
| Cefdinir | Cefdinir | 134 | 99 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 134 | 25 |
| Allopurinol | Allopurinol | 132 | 24 |
| Baclofen | Baclofen | 129 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 117 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 116 | 24 |
| Metformin Hcl | Metformin Hcl | 111 | 23 |
| Azithromycin | Azithromycin | 105 | 79 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 26 |
| Alendronate Sodium | Alendronate Sodium | 92 | 19 |
| Ozempic | Semaglutide | 90 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 89 | 22 |
| Glipizide | Glipizide | 87 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 82 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 35 |
| Montelukast Sodium | Montelukast Sodium | 73 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 69 | 14 |
| Estradiol | Estradiol | 68 | 15 |
| Telmisartan | Telmisartan | 63 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 15 |
| Eliquis | Apixaban | 55 | suppressed |
| Methylprednisolone | Methylprednisolone | 54 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 11 |
| Simvastatin | Simvastatin | 49 | 14 |
| Buspirone Hcl | Buspirone Hcl | 45 | suppressed |
| Pregabalin | Pregabalin | 45 | 15 |
| Meclizine Hcl | Meclizine Hcl | 44 | 11 |
| Gemfibrozil | Gemfibrozil | 41 | suppressed |
| Lovastatin | Lovastatin | 41 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 40 | 12 |
| Tradjenta | Linagliptin | 40 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Eszopiclone | Eszopiclone | 36 | suppressed |
| Fluconazole | Fluconazole | 36 | 27 |
| Primidone | Primidone | 36 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Celecoxib | Celecoxib | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | 11 |
| Glipizide Er | Glipizide | 27 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 15 |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Nystatin | Nystatin | 19 | 11 |
| Spironolactone | Spironolactone | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 11 |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $429.48 · 16 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, FARXIGA, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, REPATHA, REXULTI, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error